Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma is a type of blood cancer that occurs when the disease returns after treatment or does not respond to initial therapies, leading to a range of symptoms and complications.
Multiple Myeloma: Testing ISB 2001
We are investigating a new drug called ISB 2001 for patients with relapsed or refractory multiple myeloma. This trial aims to see how well it works in treating this challenging condition.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centre Hospitalier Universitaire De Lille
Maladies du sang
La Madeleine, France
Centre Hospitalier Universitaire De Nantes
Hematology
Nantes, France
Hopital Saint Antoine
Hematology
Quinze-Vingts, France
Sponsor: IGI Therapeutics S.A.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.